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ing the procoagulant activity of the substratum-adherent platelets.
To gain further insight into the procoagulant activity of collagen-adherent platelets we used a parallel plate perfusion system14 that allowed us to quantify platelet-mediated coagulation in human nonanticoagulated blood at venous blood flow. The procoagulant activity of collagen-adherent platelets was differentiated from that of platelet thrombi by the use of a potent and selective antagonist of GPIIb-IIIa, R&-9883. This compound was infused into normal blood via a mixing device,I5 resulting in a complete inhibition of platelet thrombus formation but without a concomitant inhibition of platelet adhesion to the collagen surface. The results obtained provide evidence for the importance of collagenadherent single platelets and the platelet F.X activation complex in mediating coagulation in flowing human blood.
3816
KIRCHHOFER ET AL chloromethylketone (F.IXai), was obtained from Dr David Stern (Columbia University, New York, NY). Human collagen type 111 was purified by salt precipitation, as described previously.14 Fibril formation was induced by dialyzing a solution of 1 mg/mL of collagen type I11 in 0.1 m o m acetic acid against 20 mmoVL Na2HP04, pH 7.5, at 4°C for 24 hours. The activity of the preparations were tested in the aggregometer using human plasma and they were stored at 4°C until used in the perfusion experiments. Ro 44-9883 (molecular weight [MW] 468.5) was used as an inhibitor of platelet aggregation. The structure and its antithrombotic activities were described previously. '8-20 Briefly, this compound is a potent and reversible, nonpeptide antagonist of the platelet fibrinogen receptor GPIIb-IIIa18 and inhibits platelet aggregation in plasma with an ICso of 30 nmol/ L.I8 Ro 44-9883 is highly selective for GPIIb-IIIa and does not inhibit other Arg-Gly-Asp (RGD)-dependent receptors of the integrin family, including the closely related vitronectin receptor Currently, R0 44-9883 (lamifiban) is in the clinical development stage and showed promising results in patients with unstable angina."
Perfusion experiments with infusion of the GPIIb-IIIa antagonist to normal nonanticoagulated human blood. Human collagen type 111 was sprayed in fibrillar form onto Thermanox plastic coverslips (Miles Lab, Naperville, IL) at a concentration of 20 pg/cm*. The collagen-coated coverslips were dried for several hours at room temperature, washed with 0.9% NaCl solution over a period of 1 hour, and kept in NaCl solution containing 0.1% bovine serum albumin until they were used for the perfusion experiments. The coverslips were positioned in the three parallel plate perfusion chambers and the entire system, including tubings, mixing devices, and parallel plate chambers, was filled with phosphate-buffered saline (PBS)-0.1% bovine serum albumin (BSA). The experimental system was described re~ently.'~ Blood was then drawn from the antecubital vein of a healthy donor directly into a Plexiglas distribution block where the blood was separated into three tubings. The blood flow was 1 mL/min and was controlled by three individual roller pumps positioned distal to the parallel plate perfusion devices. Immediately before entering the mixing chambers, the flowing blood was supplemented with 500 nmollL (blood concentration) of Ro 44-9883 or PBS-0.1% BSA (controls) at a rate of 50 &/min. resulting in a final concentration of 5% in the blood. R0 44-9883 was diluted in PBS-0.1 % BSA and was infused into the flowing blood by l-mL glass syringes (Hamilton; Bonaduz AG, Bonaduz, Switzerland) via an infusion pump (Infu 362; Datex AG, Uhwiesen, Switzerland). The infusion solutions were mixed with the blood in parallel in the three mixing chambers, each containing a rotating magnetic stir bar. The homogenous blood-inhibitor mixture then entered three parallel plate perfusion devices containing the collagen-coated coverslips. The blood flow of 1 mL/min resulted in a shear rate of 65/s on the collagen surface, which corresponded to venous blood flow conditions. After 5.5 minutes of perfusion, the wash solution (PBS) was connected to the distribution block without interrupting the flow. During the 3 minutes of washing, the inhibitor infusion of 50 pL/ min was maintained. The mixing device was then disconnected from the parallel plate devices, which were subsequently perfused at 1 mL/min for 2 minutes with 3% paraformaldehyde in PBS (for immunochemical staining) after a brief intemption of flow (approximately 5 seconds). For morphometrical examinations, we used 2.5% glutaraldehyde in 0.1% cacodylate buffer, pH 7.4, containing 2.5 mmoV L CaCI, and 0.9 mmoVL MgCl, instead of 3% paraformaldehyde. The coverslips were then removed from the chambers and incubated in fresh fixative for an additional 30 minutes and stored in PBS-0.03% azide and in cacodylate buffer containing 7% sucrose for immunochemical staining and morphometrical analysis, respectively.
Determination ofjbrinopeptide A (FPA) levels. FPA levels were measured in the blood leaving the perfusion device (postchamber).
For that purpose, a second mixing device was positioned between the parallel plate perfusion chambers containing noncoated or collagencoated coverslips and the roller pumps. This second mixing device served to mix the blood with an anticoagulant cocktail (32 mg/mL trisodium-citrate, 1,000 IUlmL heparin, and 1 TIUlmL aprotinin) to prevent further FPA generation. The anticoagulant cocktail was supplied by an additional roller pump distal to the perfusion chambers at a flow rate of 0.1 mL/min resulting in a mixing ratio of I : 10 (anticoagulant cocktaiUblood). The blood flow rate at the distal end of the mixing device was 1.1 mL/min, which resulted in a blood flow rate of 1 mL/min (shear rate, 65/s) over the cover slip, consistent with the perfusion experiments described above. The anticoagulated blood was collected from the roller pumps into polypropylene tubes over a period of 4.5 minutes. After centrifugation, the platelet poor plasma was stored at -20°C until the FPA concentrations were determined according to the manufacturer's instructions (enzymelinked immunosorbent assay [ELISA] FPA; Boehringer Mannheim GmbH, Mannheim, Germany). For some experiments, a T-branching was used instead of the distribution block and mixing device and was positioned upstream to the perfusion chambers. The T-branching served to infuse the wash buffer and fixative. Quantc$cation of platelets, platelet thrombi and jibrin on cross sections. After the perfusion experiments, the coverslips were embedded in Epon (Fluka Chemie, Buchs, Switzerland) and semithin sections perpendicular to the blood flow direction were prepared as described previously." The cross-sections were stained with 0.01% toluidine blue and 0.01% fuchsin and the deposition of platelets, platelet thrombi, and fibrin was determined at IO-pm intervals along the length (8 mm) of the sections using a Zeiss Standard microscope.** Fibrin coverage was measured as the total of both the fibrin deposited on the collagen surface and on adherent platelets. Platelet adhesion was defined as the coverage with both the nonspread platelets in contact with collagen (contact platelets) and the platelets spread on collagen (spread platelets). Platelet thrombi were defined as platelet aggregates that were greater than 5 pm. The measurements were from a coverslip section 1 mm downstream from the flow entrance. In certain experiments, the height of the fibrin layer was also determined. For this purpose, we used coverslip sections further downstream at a position 7 mm from the flow entrance, because the fibrin deposition at this position showed less variation between individual coverslips.
Immunogold-silver staining offibrin and platelets. After the perfusion experiments, the coverslips were incubated with either 2.5 pg/mL of monoclonal antifibrin antibody (for fibrin staining) or with 10 pg/mL of monoclonal anti-GPIIb-IIIa antibody pl-62 (for platelet staining) in PBS. After washing with PBS, the coverslips were incubated at room temperature for 30 minutes with 5 nm gold-labeled antimouse antibody (Auro Probe LM; Amersham, Amersham, UK) diluted 1:50 in PBS for fibrin staining and diluted 1:10 for platelet staining, respectively. The coverslips were then washed with PBS, treated for 10 minutes with 2% glutaraldehyde in PBS, and washed with PBS and distilled water. After incubation with silver enhancer for 10 to 15 minutes (IntenSE M; Amersham), the coverslips were fixed with Rapidfix (Eastman Kodak, Rochester, NY) and thoroughly washed in distilled water. After air-drying, the coverslips were embedded in Merckoglass (Merck, Darmstadt, Germany) and examined under the microscope (Zeiss Axiophot; Carl Zeiss, Oberkochen, Germany). bution block and a mixing device in front of the perfusion chambers containing the collagen-coated coverslips. This resulted in an appreciable activation of the coagulation system when compared with conditions in which the distribution block and mixing device was omitted and replaced with a T-branching. Postchamber FPA levels increased from 33.9 t 9.4 ng/nL (13 donors) with the T-branching setting to 95.4 ? 13.2 ng/mL (21 donors) when distribution block and mixing device were included. Similarly, fibrin coverage increased from 44.3% 5 14.6% (8 donors) to 98.7% t 1.2% (13 donors).
RESULTS

Activation
Fibrin deposition and FPA generation mediated by the collagen-adherent platelet layer. Platelet thrombus formation was prevented by blocking the platelet fibrinogen receptor GPIIb-IIIa with the synthetic inhibitor R0 44-9883,18s20 allowing us to specifically determine the procoagulant activity of the collagen-adherent platelets. This compound inhibits ADP-induced platelet aggregation in plasma with an IC50 value of 30 nm~l/L.'~ It was shown that the inhibitor did not induce conformational changes on GPIIb-IIIa,2°.23 and further studies showed that the compound neither affected basal intracellular calcium levels or pH of unstimulated platelets nor the calcium and pH increases in response to agonist^.'^ The GPIIb-IIIa antagonist R0 44-9883 was infused at a concentration that completely inhibits platelet aggregation (500 nmoyL) into normal human blood under venous flow conditions (shear rate, 6%). This resulted in a complete inhibition of platelet thrombus formation as shown on cross-sections (Fig 1A and B) and by a platelet-specific immunostaining (Fig 1C and D) . Nevertheless, platelets were found to avidly adhere to the collagen surface as shown on cross-sections and by a platelet-specific immunogold staining on en face preparations (Fig 1B and D) . Moreover, despite inhibition of platelet thrombus formation, fibrin was deposited on the collagen surface, as shown on cross-sections (Fig 1B) and on en face preparations after fibrin-specific immunostaining (Fig 1F) . The fibrin deposited on top of the adherent platelets also contained single platelets and erythrocytes (Fig 1B) . This explains the heterogeneous platelet distribution pattern on stained en face preparations, because the staining visualized all platelets, including collagen-adherent and fibrin-associated platelets (Fig 1D) .
A quantitative analysis on cross-sections showed that infusion of the GPIIb-IIIa antagonist reduced the coverage of the collagen layer with platelet thrombi from 10.7% to 0% (Fig 2a) . Conversely, fibrin formation determined as FPA levels in the postchamber blood increased from 95.4 2 13 ng/mL to 203.1 t 33.1 ng/mL when platelet aggregation was inhibited (Fig 2b) . Similarly, platelet adhesion (contact + spread platelets) determined as the percentage of coverage of the collagen surface increased from 19.9% t 2.2% to 3 1.8% 2 2.4%. The coverage with contact platelets increased as well from 0.4% ? 0.07% to 2% 2 0.4%. Thus, the ratio of contact to spread platelets increased from 2% in control to 6%. Platelet adhesion was measured on cross-sections 1 mm downstream from the flow entrance on the coverslip.
Further downstream, at a position 7 mm distal to the entrance, platelet adhesion in control experiments was only 8.9% 2 0.4% and increased to 35.1% 2 2.3% by infusion of the GPIIb-IIIa antagonist. The lower platelet adhesion of controls at the downstream position is probably due to the higher consumption of platelets from the boundary layer by the upstream deposited platelet thrombi. This finding is in full agreement with the previously reported axial-dependence of platelet deposition in flowing, nonanticoagulated
We next examined whether the increased procoagulant activity measured as elevated FPA levels was paralleled by an increased fibrin deposition on the coverslips. Table 1 shows that, in controls, about 50% of the coverslip surface was covered with a fibrin layer of less than 5 pm and only 10% was covered with a layer greater than 10 pm. In contrast, in the absence of platelet thrombus formation, ie, with infusion of the GPIIb-IIIa antagonist, the surface coverage with a fibrin layer greater than 10 pm was up to 45% and only 7% was covered with fibrin less than 5 pm in height (Table 1) .
Fibrin jiber deposition mediated by adherent single platelets. To better visualize fibrin associated with adherent platelets, the standard perfusion period of 5.5 minutes was reduced to 3.5 minutes, resulting in reduced fibrin density. A fibrinspecific immunostaining strongly suggested that fibrin formation under control conditions was platelet-associated ( Fig 3A) . Similarly, with infusion of the GPIIb-IIIa antagonist, the single platelets that adhered to collagen formed the nuclei for fibrin fiber formation (Fig 3B) . The greater density of fibrin fibers as compared with controls ( Fig 3A) can be attributed to the increased platelet density on the collagen surface. Note that the growth direction of fibrin fibers originating from single platelets is not parallel to the blood flow direction ( Fig  3A) . This was most likely due to blood flow disturbances caused by the nearby deposited platelet thrombus.
Role of the intrinsic F.X activation complex in jibrin formation. To further establish that fibrin formation was dependent on adherent platelets, we used F.Mai as a selective inhibitor of the F.X activation complex. Coinfusion of the GPIIb-IIIa antagonist and F.IXai to the flowing blood resulted in a complete inhibition of fibrin deposition (Fig 4C) as compared with infusion of the GPIIb-IIIa antagonist alone ( Fig  1F) . Platelets adhered to the collagen surface as a dense monolayer (Fig 4A and B) , and, frequently, leukocytes were bound to single platelets (Fig 4A) . Most significantly, fibrin deposition on the coverslips determined by morphometry as well as postchamber FPA levels were inhibited by more than 90% ( Table 2 ), indicating that fibrin formation by single, adherent platelets is dependent on the intrinsic F.X activation complex.
The observed inhibitory effect of F.IXai allowed us to reduce fibrin density for immunostainings with a standard perfusion period of 5.5 minutes. For that purpose, the GPIIb-IJIa antagonist Ro 44-9883 was coinfused with a low concentration (12.5 nmol/L) of F.IXai. The result showed that, similar to the findings using a shorter perfusion period and infusion of Ro 44-9883 alone (Fig 3B) , the fibrin fibers originated from deposited single, adherent platelets (data not shown). Fibrin and platelet deposition t o exposed collagen in the presence of infused GPllb-llla antagonist. Using a parallel plate perfusion system, collagen-coated coverslips were exposed for 5.5 minutes t o normal human nonanticoagulated blood supplemented with 500 nmol/L of GPllb-llla antagonist (B, D, and F) or with buffer (control; A, C, and E). After washing and fixation, the coverslips were used for immunostaining or for preparing cross-sections after embedding in Epon. (A and B) Cross-sections stained with fuchsin-toluidine solution (arrowheads indicate spread platelets). (C and D) Immunogold-silver staining of platelets and platelet thrombi (en face view) using a GPllb-Ma-specific MoAb. (E and F) Immunogold-silver staining of fibrin (en face view) using a fibrin-specific MoAb. L, leukocyte; T, platelet thrombus; F, fibrin fibers; P, single platelet; E, erythrocyte. Arrows indicate spread platelets. The bar in (A) represents 20 p m (for A and B) and that in (C) represents 50 p m (for C through F). In (C) through (F), the blood flow direction was from left t o right.
This conclusion is based on results obtained from measuring thrombus formation. Infusion of the GPIIb-IIIa antagonist postchamber FPA levels and fibrin deposition to the exposed Ro 44-9883 (lamifiban), which prevented platelet thrombus collagen surface mediated by the collagen-adherent platelet formation, resulted in the deposition of a collagen-adherent layer in the presence or absence of concomitant platelet platelet layer that retained the full capacity to promote coag- dation. In fact, both FPA and fibrin deposition were increased and correlated with the surface coverage of adherent platelets. This suggested that coagulation was dependent on the collagen-adherent platelets rather than the presence of deposited platelet thrombi. The reason for the increased platelet adhesion with infusion of the GPIIb-IIIa antagonist is most likely due to a higher concentration of platelets in the boundary layer as compared with the situation in control experiments in which the platelet concentration near the collagen surface was reduced by the forming platelet thrombi. Evidence for such mechanisms is provided by experiments with a similar flow system, in which collagen was exposed to blood containing the platelet aggregation inhibitor clopidogrel.26
In accordance with the view that the collagen-adherent platelets are the predominant mediators of coagulation, immunostaining experiments showed that adherent single platelets formed the nuclei for fibrin fiber formation under control conditions as well as with infusion of the GPIIb-IIIa antagonist. In control experiments, fibrin fibers also originated from small platelet aggregates, whereas large platelet thrombi, in most cases, did not contain much stained fibrin (Figs 3A and IE). However, fibrin was detectable at the thrombus base anchoring the thrombi to the collagen surface (data not shown). This finding could be interpreted to be in agreement with in vitro experiment^'^ in that the strong collagen stimulus for these anchoring platelets and adherent single platelets shortened their lag phase to acquire a procoagulant surface and promote fibrin formation, whereas platelets contained in the thrombi and not exposed to collagen required more time for this process. Therefore, the time period of 5.5 minutes of the experiments may have been too short for the main body of platelet thrombi to develop a procoagulant surface. Besides receiving a collagen stimulus, the anchoring platelets were exposed the longest to soluble agonists such as thrombin, which may also have contributed to an earlier procoagulant activity as compared with platelets contained in the thrombi.
The fibrillar collagen surface represented the primary stimulus for platelets to adhere and to acquire a procoagulant state. In addition, the thrombin produced in this system, which was indirectly measured as the generated FPA, may For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From have functioned as an amplifying costimulus. In vitro experiments showed that a combined stimulus of collagen and thrombin enhanced the rate of F.Xa generation by the platelet F.X activation complex as compared with thrombin alone.' To examine whether fibrin deposition mediated by the collagen-adherent platelet layer involved the F.X activation complex, we coinfused F.IXai, which competitively inhibits the binding of F.IXa to activated platelet^.^' This resulted in a complete inhibition of FPA generation and fibrin deposition, suggesting that coagulation was entirely mediated by the intrinsic F.X activation complex on adherent platelets, most of which were spread on the collagen surface. It seems very unlikely that contact platelets accounting for less than 6% of the adherent platelets significantly contributed to fibrin deposition. Consistent with these results, we previously showed that fibrin formation in control experiments without infusion of the GPIIb-IIIa antagonist is also entirely dependent on F.IXa enzymatic activity.'* Our experimental conditions with infusion of the GPIIbIIIa antagonist that resulted in the blockade of GPIIb-IIIa function may resemble thrombasthenic conditions, which are characterized by reduced or functionally inactive expression of GPIIb-IIIa on platelets.2Y Weiss et al" showed that, on exposure of collagen-containing subendothelium to blood of thrombasthenic patients, an adherent platelet monolayer was formed and fibrin deposition was slightly increased, results similar to our findings. In contrast to our results, platelet adhesion was not increased, which was most likely related to the higher shear rate (650k) and the use of subendothelium instead of collagen.23 Based on our data, we suggest that the procoagulant activity of the platelet monolayer represents the underlying mechanism for the fibrin deposition observed in the study of Weiss et al."
GPIIb-I1Ia is known to play an essential role in the adhesion of platelets to Therefore, it was somewhat unexpected to find numerous single platelets within the fibrin meshwork that covered the collagen-adherent platelet layer when the GPIIb-IIIa antagonist was infused. However, it is possible that platelet adhesion to a dynamically evolving fibrin network in flowing nonanticoagulated blood is different from adhesion to preformed fibrin" and may depend on additional mechanisms. Nevertheless, the most plausible explanation for the presence of fibrin-adherent platelets is that they became entrapped in the forming fibrin meshwork in a nonspecific manner. Consistent with this interpretation we also detected numerous erythrocytes within the fibrin meshwork; their interaction with fibrin, especially under venous flow conditions, is thought to be rather unspecific. These data suggest that, despite the absence of platelet thrombi caused by infusion of the GPIlb-IIIa antagonist, the deposited fibrin together with entrapped single platelets and erythrocytes may form a loosely packed hemostatic plug at the site of vessel damage. It is tempting to speculate that, in regard to the intended use of GPIIb-IIIa antagonists for chronic antithrombotic therapy, the procoagulant activity of single platelets adhering to exposed subendothelial collagen might reduce the antihemostatic impact of such therapies.
Our experimental system caused minor activation of coagulation due to the passage of the blood through the Plexiglas components. In addition, platelet activation measured as pthromboglobulin levels increased by using the mixing device." This preactivation resulted in a greater fibrin deposition on the collagen-coated coverslips in normal blood as compared with conditions without mixing device (our data) and other report^.'^.'^ By shortening the perfusion period or by infusing low concentrations of F.IXai, the fibrin deposition could be reduced. Immunostainings clearly indicated that, under these conditions, the fibrin deposition was mainly mediated by the collagen-adherent platelet layer, as it was with infusion of the GPIIb-IIIa antagonist, suggesting that the preactivation in our system did not influence the interpretation of our results.
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In conclusion, we show that collagen-adherent platelets are essential in promoting coagulation in a human blood flow system. Thrombin generation mediated by collagenadherent platelets may constitute an important mechanism for further platelet activation as well as fibrin deposition in thrombosis. We showed further that the procoagulant activity of collagen-adherent platelets depends on FJXa enzymatic activity. Therefore, the intrinsic F.X activation complex might represent a promising target for developing new classes of antithrombotics. "   Fig 4. Role of F.IXa in fibrin deposition mediated by collagenadherent platelets. Collagen-coated coverslips were exposed for 5.5 minutes to human blood supplemented with both GPllb-llla antagonist and F.IXai. The coverslips were processed for immunostaining and staining of cross-sections as described in Fig l. Using the parallel plate perfusion system, collagen-coated coverslips were exposed for 5.5 minutes to flowing human blood with infusion of the GPllb-llla antagonist Ro 44-9883 (GPllb-llla antagonist) and with or without coinfusion of 50 nmol/L F.IXai (GPllb-llla antagonist + F.IXai). The surface coverage with deposited platelet thrombi (>5 pm in height), platelet adhesion (contact + spread platelets), and fibrin was determined on stained cross-sections as described in the Materials and Methods. FPA levels were measured in plasma derived from postchamber blood using an ELISA. The values represent the mean z SEM of 11 donors (GPllb-llla antagonist) and 5 to 10 donors (GPllb-llla antagonist + F.IXai).
-
